Series A-1 Convertible Preferred Stock⁽¹⁾

Series A-1 Convertible Preferred Stock⁽¹⁾

Series B Convertible Preferred

Stock⁽¹⁾

(8)

(8)

11/19/2020

11/19/2020

11/19/2020

C

C

C

881,156

185,908

889,186

(8)

(8)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C.	20549
---------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
	0.5						

D⁽³⁾

D⁽⁴⁾

D⁽²⁾

Check this box if no longer subject to Section 16. Form 4 or Form 5

	ion 1(b).	ue. See		File	d pursu	ant to Se	ection 16(a)	of the Se	curiti	es Exchange	e Act of 193	34		hours	per respo	onse:	0.5	
					or S	ection 30	O(h) of the Ir	nvestmen	t Con	npany Act of	1940							
l	d Address of	Reporting Person* S L P/IL					and Ticker			mbol <u> [OLMA</u>]	(Chec	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owne Officer (give title below) Other (specific below)					
(Last) 44 MON 40TH FL	ΓGOMERY	Sirst)	(Middle)		3. Date 11/18/		est Transac	tion (Mon	th/Da	ay/Year)								
(Street) SAN FRANCI	SCO C	Α	94104		4. If An	nendmer	nt, Date of C	Original Fi	led (f	Month/Day/Y	rear)	6. Indi		d by One	Reporti	theck Applicang Person One Reporting	,	
(City)	(S	State)	(Zip)															
			Table I - Nor	n-Deriv	ative	Secur	ities Acq	uired,	Dis	posed of,	or Ben	eficially C	wned					
1. Title of S	ecurity (Inst	r. 3)		2. Transa Date (Month/D		Execu	eemed ution Date,	3. Transac Code (I 8)		4. Securitie Disposed C	es Acquired Of (D) (Instr.	(A) or 3, 4 and 5)	securities Beneficially Owned Following Reported			Direct Ir Indirect B tr. 4) C	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			С		1,129,40)4 A	(8)	1,129,404		104 D ⁽²⁾			
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			С		889,180	6 A	(9)	2,018,	590	I) (2)		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			С		760,15	5 A	(10)	2,778,	,745	I) ⁽²⁾		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			P		613,918	8 A	\$19	3,392,	,663	I) (2)		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			С		881,150	6 A	(8)	881,1	156	I) (3)		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			C		673,28	1 A	(9)	1,554,	,437	I) (3)		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			C		522,403	3 A	(10)	2,076,	,840	I) (3)		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			P		446,425	5 A	\$19	2,523,	265	I	O ⁽³⁾		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/	/2020			C		100,700		(8)	185,9	808	I	O ⁽⁴⁾		
Common	ommon stock, \$0.0001 par value ⁽¹⁾			11/19/2020				С		101,784	4 A	(9)	287,6	592	I	O ⁽⁴⁾		
Common	stock, \$0.00	001 par value ⁽¹⁾		11/19/2020		_		C		73,399		(10)	301,071		I	O ⁽⁴⁾		
Common	stock, \$0.00	001 par value ⁽¹⁾					P		74,991	A	\$19	436,0)82	I)(4)			
			Table II -										vned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	on Date, Transaction Derivative Expiration Date Securities (Month/Day/Year) Derivative		 		8. Price of Derivative Security (Instr. 5) Benefic Owned Followin Report		ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirec Beneficia Ownershi (Instr. 4)						
				Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		Transac (Instr. 4)	tion(s)			
Stock Option (Right to buy) ⁽⁵⁾	\$19	11/18/2020		A		21,520		(6)		11/17/2030	Common stock, \$0.0001 par value	21,520	\$0	21,5	20	I(2)	See footnote ⁽⁵	
Stock Option (Right to buy) ⁽⁵⁾	\$19	11/18/2020		A		21,520		(7)		11/17/2030	Common stock, \$0.0001 par value	21,520	\$0	21,5	20	I ⁽⁵⁾	See footnote ⁽⁵	
Stock Option (Right to buy) ⁽⁵⁾	\$19	11/18/2020		A		21,520		(7)		11/17/2030	Common stock, \$0.0001 par value	21,520	\$0	21,5	20	I ⁽⁵⁾	See footnote ⁽⁵	
Series A-1 Convertible Preferred	(8)	11/19/2020		C			1,129,404	(8)		(8)	Common stock, \$0.0001	1,129,404	\$0	0		D ⁽²⁾		

Common stock, \$0.0001 par value

Common stock, \$0.0001 par value

Common stock, \$0.0001

par value

881,156

185,908

889,186

\$<mark>0</mark>

\$<mark>0</mark>

\$<mark>0</mark>

0

0

(8)

(8)

			Table II - De				ired, Disp				ned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		rivative Expiration Date (Month/Day/Yea quired (A) or sposed of (D)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ate Securities Und Year) Derivative Sec		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)				
Series B Convertible Preferred Stock ⁽¹⁾	(9)	11/19/2020		С			673,281	(9)	(9)	Common stock, \$0.0001 par value	673,281	\$0	0	D ⁽³⁾			
Series B Convertible Preferred Stock ⁽¹⁾	(9)	11/19/2020		С			101,784	(9)	(9)	Common stock, \$0.0001 par value	101,784	\$0	0	D ⁽⁴⁾			
Series C Convertible Preferred Stock ⁽¹⁾	(10)	11/19/2020		С			760,155	(10)	(10)	Common stock, \$0.0001 par value	760,155	\$0	0	D ⁽²⁾			
Series C Convertible Preferred Stock ⁽¹⁾	(10)	11/19/2020		С			522,403	(10)	(10)	Common stock, \$0.0001 par value	522,403	\$0	0	D ⁽³⁾			
Series C Convertible Preferred Stock ⁽¹⁾	(10)	11/19/2020		С			73,399	(10)	(10)	Common stock, \$0.0001 par value	73,399	\$0	0	D ⁽⁴⁾			
I	d Address of	Reporting Person*											,				
(Last) 44 MON 40TH FL	ГGOMERY OOR	(First)	(Middle)														
(Street) SAN FRA	ANCISCO	CA	94104														
(City)		(State)	(Zip)														
		Reporting Person*	FUND L P														
(Last) 44 MON 40TH FL	ГGOMERY	(First)	(Middle)														
(Stroot)																	

SAN FRANCISCO CA

SAN FRANCISCO CA

BVF I GP LLC

1. Name and Address of Reporting $\mathsf{Person}^{^\star}$

(State)

(First)

(State)

(First)

(State)

(First)

BIOTECHNOLOGY VALUE FUND II LP

44 MONTGOMERY ST., 40TH FLOOR

1. Name and Address of Reporting Person*

44 MONTGOMERY STREET

SAN FRANCISCO CA

BVF II GP LLC

1. Name and Address of Reporting Person*

(City)

(Last)

(Street)

40TH FL

(Street)

(City)

(Last)

94104

(Zip)

(Middle)

94104

(Zip)

(Middle)

94104

(Zip)

(Middle)

44 MONTGOMERY	ST., 40TH FLOOR								
(Street) SAN FRANCISCO	CA	94104							
(City)	(State)	(Zip)							
1. Name and Address of Biotechnology V	Reporting Person* Salue Trading Fund	I OS LP							
(Last) P.O. BOX 309 UGL	(First) AND HOUSE	(Middle)							
(Street) GRAND CAYMAN	E9	KY1-1104							
(City)	(State)	(Zip)							
1. Name and Address of BVF Partners OS									
(Last) P.O. BOX 309 UGLA	(First) AND HOUSE	(Middle)							
(Street) GRAND CAYMAN	E9	KY1-1104							
(City)	(State)	(Zip)							
1. Name and Address of BVF GP HOLDI	· -								
(Last) 44 MONTGOMERY	(First) 7 ST., 40TH FLOOR	(Middle)							
(Street) SAN FRANCISCO	CA	94104							
(City)	(State)	(Zip)							
1. Name and Address of BVF INC/IL	Reporting Person*								
(Last) 44 MONTGOMERY 40TH FL	(First) STREET	(Middle)							
(Street) SAN FRANCISCO	CA	94104							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person* <u>LAMPERT MARK N</u>									
(Last) 1 SANSOME ST 30TH FL	(First)	(Middle)							
(Street) SAN FRANCISCO	CA	94104							
(City)	(State)	(Zip)							

Explanation of Responses

1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF GP"), BVF IGP LLC ("BVF GP"), BVF II GP LL

- 2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF.
- 3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by
- 4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- 5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

- 6. The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Mr. Hrustanovic's continuous service through such vesting date.
- 7. The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to Mr. Hrustanovic's continuous service on the Issuer's board of directors through each applicable vesting date.
- 8. Effective upon the closing of the Issuer's initial public offering (the "IPO") on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series A-1 Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such shares of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date
- 9. Effective upon the closing of the IPO on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series B Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such share of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.
- 10. Effective upon the closing of the IPO on November 19, 2020, as provided by the Issuer, each share of the Issuer's Series C Convertible Preferred Stock held by the Reporting Persons automatically converted on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, each such share of Preferred Stock was convertible at any time into shares of Common Stock and had no expiration date.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Partners may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners as set forth in Footnote (5).

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark 11/20/2020 N. Lampert, President Biotechnology Value Fund, L.P., By: BVF Partners L.P., its investment manager, By: BVF 11/20/2020 Inc., its general partner, By: /s/ Mark N. Lampert, President BVF I GP LLC, By: BVF GP HOLDINGS LLC, its sole 11/20/2020 member, By: /s/ Mark N. Lampert, Chief Executive Officer Biotechnology Value Fund II, L.P., By: BVF Partners L.P., its 11/20/2020 investment manager, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President BVF II GP LLC, By: BVF GP HOLDINGS LLC, its sole 11/20/2020 member, By: /s/ Mark N. Lampert, Chief Executive Officer Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, 11/20/2020 BVF Inc., its general partner, By: /s/ Mark N. Lampert, President BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, 11/20/2020 By: /s/ Mark N. Lampert, **President** BVF GP Holdings LLC, By: /s/ 11/20/2020 Mark N. Lampert, Chief **Executive Officer** BVF Inc., By: /s/ Mark N. 11/20/2020 Lampert, President /s/ Mark N. Lampert 11/20/2020 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).